Stockscreener 앱 받기
5.35
2.55%
-0.14
시장 영업 전:
5.26
-0.09
-1.68%
Lifecore Biomedical Inc 주식(LFCR)의 최신 뉴스
Lifecore Biomedical signs manufacturing deal for neurology product - Investing.com
Lifecore Biomedical Signs Agreement for Tech Transfer and Commercial Production of Neurological Injectable Product - Quiver Quantitative
Seventh late-stage project adds neurology deal for Lifecore Biomedical - Stock Titan
LFCR Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentPreliminary Results - newsline.com
Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook - Yahoo Finance
Trading Systems Reacting to (LFCR) Volatility - Stock Traders Daily
Lifecore Biomedical (LFCR) director awarded 25,907 RSUs - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock award - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907 restricted stock units - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock unit grant - Stock Titan
Lifecore Shareholders Approve New 2026 Stock Incentive Plan - TipRanks
Lifecore Biomedical (NASDAQ: LFCR) wins approval for 2026 stock plan - Stock Titan
LFCR Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Rises Despite WeaknessAnnual Financial Report - newsline.com
Lifecore Biomedical Signs Tech Transfer Agreement for Ophthalmic - Contract Pharma
Lifecore Biomedical signs ophthalmic manufacturing deal - Investing.com UK
Lifecore Biomedical, Inc. Signs Manufacturing Services Agreement with Leading Provider of Ophthalmic Disease Management Solutions - marketscreener.com
Lifecore Biomedical signs ophthalmic manufacturing deal By Investing.com - Investing.com South Africa
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer - The Manila Times
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by 75.6% as Revenue Remains UndisclosedBuyback Announcement Report - newsline.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical (LFCR) Inches Higher as Stock Approaches Key ResistanceVanna Flow - newsline.com
How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations - Yahoo Finance
LFCR Q1 2026 Earnings: EPS Falls Short of Estimates as Losses WidenEarnings Season Outlook - The Legal Advocate
LFCR Q1 2026 Earnings: Significant EPS Miss Despite Positive Stock ReactionFinal Results - newsline.com
Lifecore Biomedical (LFCR) Declines 2.6%, Testing Key Support at $4.56Hull Moving Average - The Legal Advocate
LFCR Q1 2026 Earnings: Wider Loss Than Expected Despite Positive Stock ReactionGlobal Trading Community - Newser
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference - Sahm
Lifecore CEO, CFO to meet investors at June 2-4 Chicago conference - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 Earnings Miss by Significant: Key TakeawaysCollaborative Trading Signals - Newser
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift - MSN
LFCR Stock Price, Quote & Chart | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore reaffirms 2026 guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA while targeting 12% revenue CAGR by 2029 - MSN
Lifecore Biomedical to Participate at CDMO Live Europe - The Manila Times
TradingKey - TradingKey
The sustainable advantages Lifecore Biomedical (LFCR) is developing (+0.42%) 2026-05-10Fast Rising Stocks - newser.com
Number of shareholders of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63 - MSN
LFCR Lifecore Biomedical shares slide 3.83% as Q1 2026 earnings miss estimates by 75.7% despite modest revenue growth.Social Momentum Signals - newser.com
The steady strength in Lifecore Biomedical (LFCR) story (Softens) 2026-05-08Company Analysis - newser.com
Lifecore Biomedical Q1 2026 Earnings Call Transcript - Sahm
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Maintains Target Price $6 - Moomoo
MSN Money - MSN
Lifecore Biomedical: Q1 Earnings Snapshot - theheraldreview.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-05-06 - Seeking Alpha
Lifecore Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Keybanc Initiates Coverage of Lifecore Biomedical (LFCR) with Sector Weight Recommendation - MSN
Lifecore Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifecore Biomedical Q1 Earnings Call Highlights - Yahoo Finance
2.11%
자본화:
|
볼륨(24시간):